Compare AAL & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAL | CYTK |
|---|---|---|
| Founded | 1930 | 1997 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.7B |
| IPO Year | 2004 | 2004 |
| Metric | AAL | CYTK |
|---|---|---|
| Price | $13.52 | $66.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $15.59 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 61.4M | 1.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,633,000,000.00 | $13,368,000.00 |
| Revenue This Year | $12.17 | $7.37 |
| Revenue Next Year | $4.62 | $310.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $10.09 | $53.57 |
| 52 Week High | $18.79 | $88.31 |
| Indicator | AAL | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 33.70 |
| Support Level | $13.27 | $59.10 |
| Resistance Level | $14.16 | $67.04 |
| Average True Range (ATR) | 0.40 | 2.14 |
| MACD | 0.16 | -0.43 |
| Stochastic Oscillator | 66.10 | 16.20 |
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.